Research programme: Alzheimer's disease therapeutics - Eisai

Drug Profile

Research programme: Alzheimer's disease therapeutics - Eisai

Alternative Names: AD genetics programme - Eisai; Alzheimer's disease genetics programme - Eisai

Latest Information Update: 25 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TorreyPines Therapeutics Inc
  • Developer Eisai Co Ltd
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 10 Nov 2008 TorreyPines Therapeutics sells its Alzheimer's disease genetics programme to Eisai
  • 22 Oct 2008 TorreyPines Therapeutics is actively seeking to sell/out-license this research programme (
  • 28 Sep 2007 Eisai and TorreyPines Therapeutics extend their existing genetics discovery collaboration in Alzheimer's disease for an additional year
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top